Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients

Maria Sole Basso, Pushpa Subramaniam, Mike Tredger, Anita Verma, Nigel Heaton, Mohamed Rela, Giorgina Mieli-Vergani, Anil Dhawan

Research output: Contribution to journalArticlepeer-review


CNI have improved the outcome of LT. However, their inherent potential to nephrotoxic and sometimes-inadequate immunosuppressive effect has lead to the usage of newer drugs like SRL. Aim of this study was to review children who received SRL. Thirty-seven (20 women) children post-LT, median age 10.4 yr (0.8-17.4) with a minimum follow-up of six months comprised the study group. Indications for SRL were biopsy-proven resistant acute allograft rejection (n = 12), early CR (n = 12), and CNI-induced nephropathy with MMF intolerance (n = 11). In two patients, the indication was the recurrence of BSEP disease in the allograft. In patients with acute rejection, AST normalized in 10/12 patients. In patients with CR, AST normalized in 6/12 patients. Those with renal impairment showed improvement in their creatinine levels from a mean baseline of 99-56.7 μm (p = 0.03) and their mean cystatin C was 1.02 after SRL. Side effects leading to discontinuation of SRL were seen in three patients. SRL was effective in rescuing patients with acute and chronic allograft rejection and improving renal function in CNI-induced nephropathy group.

Original languageEnglish
Pages (from-to)722-727
Number of pages6
JournalPediatric Transplantation
Issue number7
Publication statusPublished - Nov 2011


  • calcineurin inhibitors
  • children
  • liver transplantation
  • rejection
  • sirolimus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation


Dive into the research topics of 'Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients'. Together they form a unique fingerprint.

Cite this